CD274 and hepatocellular carcinoma: A retrospective analysis revealed that combining TACE, PD-(L1) inhibitors, and molecularly targeted treatments (MTT) in HCC resulted in a confirmed ORR of 60.1%, notably superior to TACE monotherapy (ORR: 32%) (38).